SEC ownership of ATOSSA THERAPEUTICS, INC.

Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001488039.

Comparable stake leader

VANGUARD GROUP INC

Disclosed value leader

VANGUARD GROUP INC

Comparable rows

3/43

Latest evidence

30 Jun 2026

Ownership snapshot CIK-linked ownership evidence from parsed SEC filings. 3 signals
Comparable ownership rows
3 of 43
Meaning: Rows with safely comparable ownership %
Latest 13D/G holder
VANGUARD GROUP INC
Source: Latest parsed Schedule 13D/G stake
Latest parsed ownership date
30 Jun 2026
Freshness: Most recent filing date in this holder set
Issuer Names, identifiers, and filing context for this profile. 2 identity fields
Issuer CIK
0001488039
Issuer location
Seattle, WA

Ownership snapshot

Top shareholders of ATOSSA THERAPEUTICS, INC. (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
VANGUARD GROUP INC
Disclosed value leader
VANGUARD GROUP INC
Comparable rows
3/43
Latest evidence
30 Jun 2026
13D/G 13F 3/4/5 Lead comparable stake: 4.5% 40 rows are not safely comparable across share classes. 13D/G row: VANGUARD GROUP INC Showing 1-8 of 43 holder rows.

Quick read

VANGUARD GROUP INC leads the comparable SEC ownership view at 4.5%.

3 of 43 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens VANGUARD GROUP INC's linked filing trail.
Comparable ownership Top 3
VANGUARD GROUP INC 4.5%
CVI Investments, Inc. 4.3%
BlackRock, Inc. 1.6%

Ownership % is shown only when SEC disclosures are safely comparable across share classes.

Detailed SEC evidence table Showing 1-8 of 43 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
VANGUARD GROUP INC
13D/G
The Vanguard Group
4.5%
Reported 13D/G · 30 Jun 2025
$4,841,495
5,833,127 shares
$0 30 Jun 2025
CVI Investments, Inc.
13D/G
4.3%
Reported 13D/G · 31 Dec 2024
$4,530,000
5,662,500 shares
$0 31 Dec 2024
BlackRock, Inc.
13D/G 13F
Company
1.6%
Reported 13D/G · 30 Jun 2025
$1,717,392
2,094,891 shares
$0 30 Jun 2025
VANGUARD CAPITAL MANAGEMENT LLC
13F
Company
13F
—
denominator unverified
$698,172
361,747 shares
— 30 Jun 2026
Steven C. Quay
3/4/5
President & CEO, Director
—
mixed-class rows
$625,666
2,405,583 shares
mixed-class rows
— 27 Mar 2026
AMERIPRISE FINANCIAL INC
13F
Company
13F
—
denominator unverified
$498,392
258,234 shares
— 30 Jun 2026
RENAISSANCE TECHNOLOGIES LLC
13F
Company
13F
—
denominator unverified
$254,843
132,043 shares
— 30 Jun 2026
GEODE CAPITAL MANAGEMENT, LLC
13F
Company
13F
—
denominator unverified
$178,343
92,382 shares
— 30 Jun 2026
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Forms 3/4/5 flow

Insider trading overview

No eligible buy or sell activity is available for this window. No eligible Buy or Sell transactions are available in this dataset since 22 Oct 2025.

Buys
$0
Insiders: 0
Sells
$0
Insiders: 0
Net
$0
Shares: 0
Window
Last 12 months
4 rolling buckets
Buy value Sell value
Shares: 0 Shares: 0
Window (months) Buy shares Sell shares Buy value Sell value Net value
0-3 0 0 $0 $0 $0
3-6 0 0 $0 $0 $0
6-9 0 0 $0 $0 $0
9-12 0 0 $0 $0 $0

Reporting owners

Insider holders from Forms 3/4/5

Showing 1-11 of 11 reporting-owner rows connected to ATOSSA THERAPEUTICS, INC.. Open a relationship link for the CIK-to-CIK filing trail.

Rows
11
Largest Forms 3/4/5 holder
Steven C. Quay
Net 12M change
$0
Latest report
12 May 2026
Name Relationship Holdings Value Past Year Net Change Change % Valuation Report Date
Steven C. Quay President & CEO, Director $625,666 Mixed 27 Mar 2026
Mark James Daniel Chief Financial Officer $37,170 Mixed 26 Mar 2026
Jonathan Finn Director $10,263 Mixed 12 May 2026
Shu-Chih Chen Director $10,102 Mixed 12 May 2026
Stephen J. Galli Director $8,802 Mixed 12 May 2026
Tessa Cigler Director $8,797 Mixed 12 May 2026
Richard I. Steinhart Director $8,797 Mixed 12 May 2026
H. Lawrence Remmel Director $7,180 Mixed 12 May 2026
Gregory L. Weaver Former EVP, CFO, & Director, Director $36 Filing P/S 15 Nov 2023
Kyle Guse CFO, Gen Counsel and Secretary Mixed 02 Mar 2023
Heather Rees Chief Financial Officer Mixed 15 May 2025

Recent insider transactions for ATOSSA THERAPEUTICS, INC.

Showing up to 300 recent insider transactions from the last 12 months.

Insider Symbol Class Transaction % SEC-reported value SEC-reported price Shares Shares owned Date Ownership
Richard I. Steinhart ATOS Common Stock Award 10,000 10,000 12 May 2026 Direct
Shu-Chih Chen ATOS Common Stock Award 10,000 10,000 12 May 2026 Direct
H. Lawrence Remmel ATOS Common Stock Award 1464.1% 10,000 10,683 12 May 2026 Direct
Jonathan Finn ATOS Common Stock Award 600.2% 10,000 11,666 12 May 2026 Direct
Stephen J. Galli ATOS Common Stock Award 166666.7% 10,000 10,006 12 May 2026 Direct
Tessa Cigler ATOS Common Stock Award 10,000 10,000 12 May 2026 Direct
Steven C. Quay ATOS Common Stock Award 282.1% 65,000 88,038 27 Mar 2026 Direct
Mark James Daniel ATOS Common Stock Award 63,000 63,000 26 Mar 2026 Direct
Steven C. Quay ATOS Common Stock Award 2386.5% 331,674 345,572 20 Jan 2026 Direct
Steven C. Quay ATOS Stock Options (right to buy) Award 950,000 950,000 20 Jan 2026 Direct
* marks a reported price that did not pass the local price check.
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .